BiotechTube
Neuromod Devices

Neuromod Devices

Dublin, Ireland· Est.
neuromod.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $14M

Overview

Neuromod Devices is a commercial-stage medical device company that has achieved a significant milestone with the FDA approval of its flagship product, Lenire, for tinnitus treatment. The company's core technology is bimodal neuromodulation, which has been validated in three large-scale, peer-reviewed clinical trials involving over 600 patients. Neuromod operates a B2B2C model, distributing Lenire through a network of over 200 clinicians across more than 130 clinics in the US and Europe, supported by a comprehensive partner platform for training and practice enablement. With a strong IP portfolio of 136+ patents across 37 countries, Neuromod is positioned as a category creator in the substantial and underserved tinnitus market.

TinnitusAuditory Disorders

Technology Platform

Bimodal neuromodulation delivering simultaneous auditory and somatosensory (tongue) stimulation to drive neuroplastic changes for tinnitus treatment.

Funding History

2
Total raised:$14M
Series B$8M
Series A$6M

Opportunities

The primary opportunity lies in addressing the vast, underserved global tinnitus market, estimated to affect ~740 million people, with the first and only FDA-approved device of its kind.
Neuromod can leverage its first-mover advantage, strong clinical data, and extensive IP portfolio to establish a new standard of care and capture significant market share through its scalable clinic-partner model.

Risk Factors

Key risks include the challenge of driving market adoption and securing insurance reimbursement in key markets like the US.
The company also faces potential competition from future entrants and must successfully execute on complex global operations, including supply chain management and quality control across a distributed network of clinic partners.

Competitive Landscape

Neuromod's Lenire device currently holds a unique position as the only FDA-approved bimodal neuromodulation treatment for tinnitus. It faces competition from broader tinnitus management approaches (sound therapy, cognitive behavioral therapy) and other investigational neuromodulation devices, but its regulatory clearance and published clinical trial data provide a significant competitive moat in the near to medium term.

More companies in Neuroscience & CNS →More companies in Ireland →